Summary
The influence of the debrisoquine/sparteine-type of oxidation polymorphism on plasma bufuralol concentration and the pattern of urine metabolites was studied in extensive and poor metabolizer subjects. (+)- and (−)-bufuralol, and (+)- and (−)-OH-bufuralol in plasma were determined by enantioselective HPLC, and urinary bufuralol and its metabolites were assayed by gas chromatography-mass spectrometry. Three hours after administration of racemic bufuralol the plasma (−)/(+) isomeric ratio for unchanged bufuralol was 1.84 in extensive metabolizers, indicating preferential clearance of the (+)-isomer through aliphatic 1′-hydroxylation and glucuroconjugation, while the (−)-isomer was mainly eliminated by aromatic 4-hydroxylation. Poor metabolizers were characterized by impaired 1′- and 4-hydroxylation, with almost total abolition of the stereoselectivity of these reactions. The data strongly suggest that both 1′- and 4-hydroxylation are catalyzed by the same enzyme. These in vivo observations are in agreement with recent in vitro data obtained in human liver microsomes from phenotyped patients and support the concept of deficiency of a highly stereoselective cytochrome P-450 isozyme as the cause of this polymorphism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ariens EJ (1984) Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 26: 663–668
Boobis AR, Murray S, Kahn GL, Roberts GM, Davies DS (1983) Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol 23: 474–481
Boobis AR, Murray S, Hampden CE, Davies DS (1985) Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1′-hydroxylase activities. Biochem Pharmacol 34: 65–71
Davies DS, Kahn GC, Murray S, Brodie MJ, Boobis AR (1981) Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol 11: 89–91
Dayer P, Courvoisier F, Balant L, Fabre J (1982a) Betablockers and drug oxidation status. Lancet 1: 509
Dayer P, Kubli A, Courvoisier F, Balant L, Fabre J (1982b) Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolizers. Br J Clin Pharmacol 13: 750–752
Dayer P, Balant L, Courvoisier F, Küpfer A, Kubli A, Gorgia A, Fabre J (1982c) The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet 7: 73–77
Dayer P, Balant L, Küpfer A, Courvoisier F, Fabre J (1983) Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents. Eur J Clin Pharmacol 24: 797–799
Dayer P, Gasser R, Gut J, Kronbach T, Robertz GM, Eichelbaum M, Meyer UA (1984) Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine/sparteine type polymorphism): Increased Michaelis constant (Km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers. Biochem Biophys Res Commun 125: 374–380
Dayer P, Balant L, Kupfer A, Striberni R, Leemann T (1985a) Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin Pharmacol 28: 317–320
Dayer P, Leemann T, Gut J, Kronbach T, Kupfer A, Francis R, Meyer UA (1985b) Steric configuration and polymorphic oxidation of lipophilic beta-adrenoceptor blocking agents: In vivo — in vitro correlations. Biochem Pharmacol 34: 399–400
Dayer P, Leemann T, Marmy A, Rosenthaler J (1985c) Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: Influence of genetic status on behavior of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol 28: 149–153
Distlerath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson GR, Guengerich FP (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260: 9057–9067
Eichelbaum M (1982) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokinet 7: 1–22
Francis RJ, East PB, McLaren SJ, Larman J (1975) Determination of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection. Biomed Mass Spectrometr 3: 281–285
Francis RJ, Allen JG, East PB, Rhane RJ (1976) The metabolism of bufuralol — Urinary metabolite: Profiles in rat, dog and man. Eur J Drug Metabol Pharmacokinet 2: 113–124
Francis RJ, East PB, Larman J (1982) Kinetics and metabolism of (+)-, (−) and (+/−)-bufuralol. Eur J Clin Pharmacol 23: 529–533
Jenner P, Testa B (1974) The influence of stereochemical factors on drug disposition. In: Di Carlo FJ (ed) Drug metabolism reviews, vol.2. Marcel Dekker, New York, p 117–184
Leemann T, Dayer P, Balant L, Buri P (1984) Direct determination of R- and S-metoprolol in biological fluids, by ion-pair-HPLC. Abstract of the 16th Annual Meeting of the USGEB, March 1984, Zürich. Experientia 40: 647
Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF (1983) Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolisers. Clin Pharmacol Ther 34: 732–737
Lennard MS, Tucker GT, Woods HF (1986) The polymorphic oxidation of β-adrenoceptor antagonists — Clinical pharmacokinetic consideration. Clin Pharmacokinet 11: 1–17
Meier PHJ, Mueller HK, Dick B, Meyer UA (1983) Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85: 682–692
Minder ER, Meier PJ, Müller HK, Minder C, Meyer UA (1984) Bufuralol metabolism in human liver: A sensitive probe for the debrisoquine-type of polymorphism of drug oxidation. Eur J Clin Invest 14: 184–189
Meyer UA, Gut J, Kronbach T, Skoda R, Meier UT, Dayer P (1986) The molecular mechanisms of common polymorphisms of drug oxidation — Evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16: 449–464
Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: Co-segregation of oxidative 0-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 38: 618–624
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dayer, P., Leemann, T., Küpfer, A. et al. Stereo- and regioselectivity of hepatic oxidation in man — Effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation. Eur J Clin Pharmacol 31, 313–318 (1986). https://doi.org/10.1007/BF00981130
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00981130